Cargando…

Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study

The simultaneous use of multiple drugs—termed ‘polypharmacy’—is often required to manage multiple physiological and biological changes and the interplay between chronic disorders that are expected to increase in association with ageing. However, by increasing the number of medications consumed, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhumaidi, Reham M., Bamagous, Ghazi A., Alsanosi, Safaa M., Alqashqari, Hamsah S., Qadhi, Rawabi S., Alhindi, Yosra Z., Ayoub, Nahla, Falemban, Alaa H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299180/
https://www.ncbi.nlm.nih.gov/pubmed/37373654
http://dx.doi.org/10.3390/jcm12123960
_version_ 1785064299856658432
author Alhumaidi, Reham M.
Bamagous, Ghazi A.
Alsanosi, Safaa M.
Alqashqari, Hamsah S.
Qadhi, Rawabi S.
Alhindi, Yosra Z.
Ayoub, Nahla
Falemban, Alaa H.
author_facet Alhumaidi, Reham M.
Bamagous, Ghazi A.
Alsanosi, Safaa M.
Alqashqari, Hamsah S.
Qadhi, Rawabi S.
Alhindi, Yosra Z.
Ayoub, Nahla
Falemban, Alaa H.
author_sort Alhumaidi, Reham M.
collection PubMed
description The simultaneous use of multiple drugs—termed ‘polypharmacy’—is often required to manage multiple physiological and biological changes and the interplay between chronic disorders that are expected to increase in association with ageing. However, by increasing the number of medications consumed, the risk of undesirable medication reactions and drug interactions also increases exponentially. Hence, knowledge of the prevalence of polypharmacy and the risk of potentially serious drug–drug interactions (DDIs) in elderly patients should be considered a key topic of interest for public health and health care professionals. Methods: Prescription and demographic data were collected from the electronic files of patients who were aged ≥ 65 years and attended Al-Noor Hospital in Makkah, Saudi Arabia, between 2015 and 2022. The Lexicomp(®) electronic DDI-checking platform was used to evaluate the patients’ medication regimens for any potential drug interactions. Results: A total of 259 patients were included in the study. The prevalence of polypharmacy among the cohort was 97.2%: 16 (6.2%) had minor polypharmacy, 35 (13.5%) had moderate polypharmacy, and 201 (77.6%) had major polypharmacy. Of the 259 patients who were taking two or more medications simultaneously, 221 (85.3%) had at least one potential DDI (pDDI). The most frequently reported pDDI under category X that should be avoided was the interaction between clopidogrel and esomeprazole and was found in 23 patients (18%). The most frequently reported pDDI under category D that required therapeutic modification was the interaction between enoxaparin and aspirin, which was found in 28 patients (12%). Conclusions: It is often necessary for elderly patients to take several medications simultaneously to manage chronic diseases. Clinicians should distinguish between suitable, appropriate and unsuitable, inappropriate polypharmacy, and this criterion should be closely examined when establishing a therapeutic plan.
format Online
Article
Text
id pubmed-10299180
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102991802023-06-28 Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study Alhumaidi, Reham M. Bamagous, Ghazi A. Alsanosi, Safaa M. Alqashqari, Hamsah S. Qadhi, Rawabi S. Alhindi, Yosra Z. Ayoub, Nahla Falemban, Alaa H. J Clin Med Brief Report The simultaneous use of multiple drugs—termed ‘polypharmacy’—is often required to manage multiple physiological and biological changes and the interplay between chronic disorders that are expected to increase in association with ageing. However, by increasing the number of medications consumed, the risk of undesirable medication reactions and drug interactions also increases exponentially. Hence, knowledge of the prevalence of polypharmacy and the risk of potentially serious drug–drug interactions (DDIs) in elderly patients should be considered a key topic of interest for public health and health care professionals. Methods: Prescription and demographic data were collected from the electronic files of patients who were aged ≥ 65 years and attended Al-Noor Hospital in Makkah, Saudi Arabia, between 2015 and 2022. The Lexicomp(®) electronic DDI-checking platform was used to evaluate the patients’ medication regimens for any potential drug interactions. Results: A total of 259 patients were included in the study. The prevalence of polypharmacy among the cohort was 97.2%: 16 (6.2%) had minor polypharmacy, 35 (13.5%) had moderate polypharmacy, and 201 (77.6%) had major polypharmacy. Of the 259 patients who were taking two or more medications simultaneously, 221 (85.3%) had at least one potential DDI (pDDI). The most frequently reported pDDI under category X that should be avoided was the interaction between clopidogrel and esomeprazole and was found in 23 patients (18%). The most frequently reported pDDI under category D that required therapeutic modification was the interaction between enoxaparin and aspirin, which was found in 28 patients (12%). Conclusions: It is often necessary for elderly patients to take several medications simultaneously to manage chronic diseases. Clinicians should distinguish between suitable, appropriate and unsuitable, inappropriate polypharmacy, and this criterion should be closely examined when establishing a therapeutic plan. MDPI 2023-06-10 /pmc/articles/PMC10299180/ /pubmed/37373654 http://dx.doi.org/10.3390/jcm12123960 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Alhumaidi, Reham M.
Bamagous, Ghazi A.
Alsanosi, Safaa M.
Alqashqari, Hamsah S.
Qadhi, Rawabi S.
Alhindi, Yosra Z.
Ayoub, Nahla
Falemban, Alaa H.
Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study
title Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study
title_full Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study
title_fullStr Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study
title_full_unstemmed Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study
title_short Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study
title_sort risk of polypharmacy and its outcome in terms of drug interaction in an elderly population: a retrospective cross-sectional study
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299180/
https://www.ncbi.nlm.nih.gov/pubmed/37373654
http://dx.doi.org/10.3390/jcm12123960
work_keys_str_mv AT alhumaidirehamm riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy
AT bamagousghazia riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy
AT alsanosisafaam riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy
AT alqashqarihamsahs riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy
AT qadhirawabis riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy
AT alhindiyosraz riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy
AT ayoubnahla riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy
AT falembanalaah riskofpolypharmacyanditsoutcomeintermsofdruginteractioninanelderlypopulationaretrospectivecrosssectionalstudy